GlassScriptPhysician profile
Sukhminder Singh
NPI 1417949371
$4,637.09
in general payments reported to CMS, 2019-2025
15 companies · $2,517 in 2025
The $2,517 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.53 · 2022: $406 · 2023: $628 · 2024: $1,065 · 2025: $2,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,210.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,250.61 | 2023-2025 | Caplyta |
| Abbvie INC. | $1,241.48 | 2023-2025 | Vraylar |
| Alkermes, INC. | $548.01 | 2021-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $514.92 | 2022-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $262.31 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $163.22 | 2023-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $143.64 | 2022-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $113.16 | 2022-2024 | Invega Sustenna, Invega Trinza |
| Avanir Pharmaceuticals, INC. | $106.97 | 2022 | |
| Neurocrine Biosciences, INC. | $104.66 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $63.42 | 2024 | Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $56.95 | 2023-2024 | Auvelity |
| Almatica Pharma LLC | $24.04 | 2024 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $23.12 | 2023 | Trintellix |
| Lundbeck LLC | $20.58 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukhminder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.